Thrombotic Microangiopathies clinical trials
The registry lists 52 studies for Thrombotic Microangiopathies across more than 10 countries. 21 are recruiting or about to start. 30 of them are mainly about Thrombotic Microangiopathies (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-09. Counting its 5 narrower conditions too, such as Purpura, Thrombocytopenic, Idiopathic: 668 studies, 203 open.
Get an email when these change. Save the Thrombotic Microangiopathies studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
Alexion Pharmaceuticals, Inc. (6) · Omeros Corporation (4) · Novartis Pharmaceuticals (3) · The First Affiliated Hospital of Soochow University (3) · First Affiliated Hospital of Zhejiang University (2) · University of California, San Francisco (2) · University Hospital, Rouen (2) · University Hospital, Tours (2)
What is being tested here
Drugs under test in Thrombotic Microangiopathies studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
All 3, phase 3 first
- Dec 2026N-Acetylcysteine as Therapy for Transplantation- Associated Thrombotic Microangiopathy · Phase 3 · The First Affiliated Hospital of Soochow University
- Dec 2026Complement Prospective Evaluation of Thrombotic Microangiopathy on Endothelium · Maastricht University Medical Center
- Nov 2027Construction of a Database for TMA · The First Affiliated Hospital of Soochow University
Who these studies take
Of the 18 Thrombotic Microangiopathies studies recruiting now, 12 (67%) set no upper age limit and 3 (17%) stop at 75 or younger. 9 (50%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 1 (6%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 6 (33%) | 6 (33%) |
| 18 | 17 (94%) | 17 (94%) |
| 30 | 16 (89%) | 16 (89%) |
| 40 | 16 (89%) | 16 (89%) |
| 50 | 16 (89%) | 16 (89%) |
| 65 | 16 (89%) | 16 (89%) |
| 75 | 15 (83%) | 15 (83%) |
| 85 | 15 (83%) | 15 (83%) |
Across all 52 studies, recruiting or not: 21% stop at 75 or younger and 17% at 65; 48% take children; 2% are for women only and 0% for men only; 6% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
What changed recently
From the registry's own updates since Oct 11, 2026.
Started recruiting1
- The Role of interferOn and Complement in SecondAry thRombotic micrioangiOpathyOct 28, 2026NCT07705789
Results posted1
- Ravulizumab in Thrombotic Microangiopathy After Hematopoietic Stem Cell TransplantNov 4, 2026NCT04543591
Studies
Recruiting first, then most recently updated. Showing 50 of 52. Browse all 52 → or search them.
- The Role of interferOn and Complement in SecondAry thRombotic micrioangiOpathyRecruitingNCT07705789Not applicable1 country
- TGD001 Treatment in Thrombotic MicroangiopathiesNot yet recruitingNCT07459114Phase 1/2
- Safety and Efficacy of Iptacopan in Patients With High-Risk Transplantation-Associated Thrombotic MicroangiopathyRecruitingNCT07347990Not applicable1 country
- Safety and Efficacy of Eculizumab in High-risk TA-TMARecruitingNCT07707687Phase 21 country
- TRANSPIRE: Lung Injury in a Longitudinal Cohort of Pediatric HSCT PatientsRecruitingNCT040984451 country
- Evaluate Long-term Safety, Tolerability and Efficacy of Iptacopan in Study Participants With aHUSRecruitingNCT05795140Phase 36 countries
- Efficacy and Safety of Switching From Anti-C5 Antibody Treatment to Iptacopan Treatment in Study Participants With Atypical Hemolytic Uremic Syndrome (aHUS)RecruitingNCT05935215Phase 38 countries
- Efficacy and Safety of Immunosuppression, Caplacizumab and Plasma Infusion Without Therapeutic Plasma Exchange in Immune-mediated Thrombotic Thrombocytopenic PurpuraRecruitingNCT06291025Not applicable3 countries
- Retrospective Epidemiological Study of Patients in the National Cohort of the French TMA CenterRecruitingNCT072058611 country
- Complement Prospective Evaluation of Thrombotic Microangiopathy on EndotheliumRecruitingNCT047451951 country
- Atypical Hemolytic-Uremic Syndrome (aHUS) RegistryRecruitingNCT0152218317 countries
- Identification of Plasma Biomarkers for Early Diagnosis of Transplant-associated Thrombotic MicroangiopathyRecruitingNCT061026941 country
- Thrombotic Microangiopathy (TMA) Associated With Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) In Adult PatientsRecruitingNCT070590261 country
- Efficacy and Safety Study of Narsoplimab in Pediatric Patients With High-Risk Hematopoietic Stem Cell Transplant TMARecruitingNCT05855083Phase 25 countries
- Longitudinal Cohort of Thrombosis and Hemostasis DiseasesRecruitingNCT067276691 country
- Italian iTTP RegistryRecruitingNCT063767861 country
- Study of Patients With Thrombotic Microangiopathy Associated With Mitomycin C, Treated or Not With EculizumabRecruitingNCT060983781 country
- Automated Surveillance, Alert, and Rapid Diagnosis of Thrombotic Microangiopathies: the ASARD-TMA StudyNot yet recruitingNCT05996679
- French National Cohort MATRIX "Renal and Systemic Thrombotic Microangiopathy"RecruitingNCT059912451 country
- Construction of a Database for TMARecruitingNCT056349281 country
- OMS721 Compassionate Use in Patients With Thrombotic MicroangiopathyAvailableNCT02355782
- Study to Evaluate Safety, Tolerability and Pharmacodynamics of KP104 in Participants With Thrombotic Microangiopathy Secondary to Systemic Lupus ErythematosusWithdrawnNCT05504187Phase 2
- Ravulizumab in Thrombotic Microangiopathy After Hematopoietic Stem Cell TransplantCompletedNCT04543591Phase 317 countries
- Efficacy and Safety of Iptacopan (LNP023) in Adult Patients With Atypical Hemolytic Uremic Syndrome Naive to Complement Inhibitor TherapyCompletedNCT04889430Phase 38 countries
- A Study Using Real-world Data to Examine Outcomes in Children and Adults Who Develop a Blood Clotting Disorder Called Thrombotic Microangiopathy (TMA) After Undergoing a Hematopoietic Stem Cell Transplant (HSCT).CompletedNCT0773236110 countries
- Study Evaluating the Efficacy of Eculizumab in the Treatment of Gemcitabine-induced Thrombotic MicroangiopathiesWithdrawnNCT05702996Phase 31 country
- Single Patient Expanded Access Treatment Plan For The Investigational Product NarsoplimabApproved for marketingNCT04247906
- Study of Ravulizumab in Pediatric Participants With HSCT-TMACompletedNCT04557735Phase 37 countries
- N-Acetylcysteine as Therapy for Transplantation- Associated Thrombotic MicroangiopathyActive, not recruitingNCT07279610Phase 2/31 country
- Safety and Efficacy Study of OMS721 in Patients With Atypical Hemolytic Uremic SyndromeTerminatedNCT03205995Phase 34 countries
- A Study of Pegcetacoplan for Patients With Transplant-associated Thrombotic Microangiopathy After Hematopoietic Stem Cell TransplantationCompletedNCT05148299Phase 25 countries
- The Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Adult Subjects With Immune Thrombocytopenia (ITP)WithdrawnNCT06291415Phase 15 countries
- Nomacopan (rVA576) in Transplant Associated Thrombotic MicroangiopathyTerminatedNCT04784455Phase 33 countries
- Personalized Spacing of Eculizumab Infusions Based on Therapeutic Pharmacological Monitoring (EspacECU)CompletedNCT04859608Phase 31 country
- Ravulizumab in Thrombotic Microangiopathy Associated With a TriggerTerminatedNCT04743804Phase 313 countries
- Safety and Efficacy Study of OMS721 in Patients With Thrombotic MicroangiopathiesCompletedNCT02222545Phase 212 countries
- Defibrotide Prophylaxis of Transplant Associated-Thrombotic Microangiopathy for NeuroblastomaWithdrawnNCT06182410Phase 2
- Eculizumab to Treat Thrombotic Microangiopathy/Atypical Hemolytic Uremic Syndrome -Associated Multiple Organ Dysfunction Syndrome in Hematopoietic Stem Cell Transplant RecipientsCompletedNCT03518203Phase 21 country
- Ravulizumab and COVID-19Status unknownNCT04570397Phase 31 country
- Observational Study of Elizaria® in aHUS PatientsCompletedNCT047498101 country
- Study in Adult and Pediatric Patients With HSCT-TMAWithdrawnNCT049700041 country
- A Safety and Efficacy Study of NAC in Patients With TA-TMACompletedNCT03252925Phase 31 country
- Defibrotide TMA Prophylaxis Pilot TrialCompletedNCT03384693Phase 21 country
- Risk Factors and the Effect of Plasma Exchange on Prognosis of Pregnancy-related Thrombotic MicroangiopathiesStatus unknownNCT04949698
- Incidence of Snakebite Associated Thrombotic Microangiopathy & Role of Peripheral Blood Smear as a Predictor of Clinical OutcomeStatus unknownNCT048450221 country
- Early Predictive Factors of Cardiac and Cerebral Involvement in TMACompletedNCT02134171Not applicable1 country
- A Study of an Investigational Drug, Cemdisiran (ALN-CC5), in Patients With Atypical Hemolytic Uremic SyndromeWithdrawnNCT03303313Phase 210 countries
- TTP and aHUS in Complicated PregnanciesStatus unknownNCT036055111 country
- Identification and Treatment of Thrombotic Microangiopathies in Allogeneic Stem Cell TransplantsCompletedNCT026044201 country
- Screening of TMA Patients für ADAMTS13 Activity (Adamscreen)Status unknownNCT02373267